Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Cyclerion Therapeutics (CYCN) Accumulated Depreciation & Amortization (2019 - 2022)

Cyclerion Therapeutics has reported Accumulated Depreciation & Amortization over the past 4 years, most recently at $2.2 million for Q4 2022.

  • Quarterly results put Accumulated Depreciation & Amortization at $2.2 million for Q4 2022, down 0.86% from a year ago — trailing twelve months through Dec 2022 was $2.2 million (down 0.86% YoY), and the annual figure for FY2022 was $2.2 million, down 0.86%.
  • Accumulated Depreciation & Amortization for Q4 2022 was $2.2 million at Cyclerion Therapeutics, down from $2.3 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CYCN hit a ceiling of $31.0 million in Q3 2019 and a floor of $2.1 million in Q2 2021.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $6.3 million (2020), compared with a mean of $11.9 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 29.36% in 2020 and later plummeted 90.02% in 2021.
  • Cyclerion Therapeutics' Accumulated Depreciation & Amortization stood at $21.6 million in 2019, then crashed by 52.38% to $10.3 million in 2020, then plummeted by 78.61% to $2.2 million in 2021, then dropped by 0.86% to $2.2 million in 2022.
  • The last three reported values for Accumulated Depreciation & Amortization were $2.2 million (Q4 2022), $2.3 million (Q3 2022), and $2.3 million (Q2 2022) per Business Quant data.